Coherus Biosciences | CHRS - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.84B 205M 2026-09
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Akebia Therapeutics USD 23.53M 3.19M 2025-12
ALKERMES USD 190.54M 6.1M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.68B 40M 2026-09
Baxter International USD 730M 5M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.12B 305M 2026-09
Fujifilm JPY 234.18B 4.23B 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Merck USD 2.86B 25M 2026-09
Myriad Genetics USD 122.3M 6.7M 2025-12
Pacira USD 950.8M 858.99M 2026-09
Perrigo USD 271.7M 3.01B 2026-09
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Teva Pharmaceutical Industries USD 1.01B 27M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09
Xencor USD 71.93M 5.61M 2026-09
Zoetis USD 582M 10M 2026-09